The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
复制标题
DOI：
10.1186/s40425-016-0188-z
复制
发表时间：
2016
影响因子：
10.9
通讯作者：
Dhodapkar MV
中科院分区：
文献类型：
--
作者：
Boyiadzis M;Bishop MR;Abonour R;Anderson KC;Ansell SM;Avigan D;Barbarotta L;Barrett AJ;Van Besien K;Bergsagel PL;Borrello I;Brody J;Brufsky J;Cairo M;Chari A;Cohen A;Cortes J;Forman SJ;Friedberg JW;Fuchs EJ;Gore SD;Jagannath S;Kahl BS;Kline J;Kochenderfer JN;Kwak LW;Levy R;de Lima M;Litzow MR;Mahindra A;Miller J;Munshi NC;Orlowski RZ;Pagel JM;Porter DL;Russell SJ;Schwartz K;Shipp MA;Siegel D;Stone RM;Tallman MS;Timmerman JM;Van Rhee F;Waller EK;Welsh A;Werner M;Wiernik PH;Dhodapkar MV
关于血液恶性肿瘤的生物学以及免疫系统在控制这些疾病中的作用的知识不断增加，导致了免疫疗法的开发和批准，这些免疫疗法产生了令人印象深刻的临床反应。因此，癌症免疫治疗协会（SITC）召集了一个由医生、护士、患者倡导者和患者组成的血液恶性肿瘤癌症免疫治疗指南小组，以制定多发性骨髓瘤、淋巴瘤和急性白血病患者免疫治疗临床应用的共识建议。这些建议是根据先前建立的过程，根据医学研究所的临床实践指南。在此过程中，对2004年至2014年的高影响力研究进行了系统的文献检索，并补充了专家组确定的其他文献。共识小组于2014年12月举行会议，目标是为血液恶性肿瘤患者的免疫治疗临床使用产生共识建议。在本次会议期间，共识小组投票沿着讨论用于评价和审查文献检索的支持性证据的强度。这些共识建议关注与患者选择、毒性管理、临床终点以及治疗顺序或组合相关的问题。总的来说，免疫治疗正在迅速成为一种有效的治疗策略，用于血液恶性肿瘤的管理。提供了其临床应用的循证共识建议，并将随着该领域的发展而更新。本文的在线版本（doi：10.1186/s40425-016-0188-z）包含补充材料，可供授权用户使用。
Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine’s clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves. The online version of this article (doi:10.1186/s40425-016-0188-z) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
20.3
作者：
Barker, Juliet N.;Doubrovina, Ekaterina;O'Reilly, Richard J.
通讯作者：
O'Reilly, Richard J.
影响因子：
50.5
作者：
Armitage, JO;Coiffier, B
通讯作者：
Coiffier, B
DOI：
10.1158/1078-0432.ccr-09-1339
发表时间：
2009-10-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Ansell SM;Hurvitz SA;Koenig PA;LaPlant BR;Kabat BF;Fernando D;Habermann TM;Inwards DJ;Verma M;Yamada R;Erlichman C;Lowy I;Timmerman JM
通讯作者：
Timmerman JM
影响因子：
6.5
作者：
Advani AS;McDonough S;Coutre S;Wood B;Radich J;Mims M;O'Donnell M;Elkins S;Becker M;Othus M;Appelbaum FR
通讯作者：
Appelbaum FR
影响因子：
45.3
作者：
Bollard, Catherine M.;Gottschalk, Stephen;Rooney, Cliona M.
通讯作者：
Rooney, Cliona M.